+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Rx/Reimbursement Adult Incontinence in Denmark

  • PDF Icon

    Report

  • 19 Pages
  • March 2025
  • Region: Denmark
  • Euromonitor International
  • ID: 4517573
Value sales of RX/reimbursement adult incontinence grew in 2024 in Denmark, supported by the ageing population. It is estimated that around 80% of reimbursement recipients are aged 65 and older, a group that is expanding as life expectancy increases. The ageing population, coupled with rising obesity rates, underpins the recorded growth for RX/reimbursement adult incontinence in 2024, due to the strong link between older age, obesity, and incontinence.

The Rx/Reimbursement adult incontinence in Denmark report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2020-2024, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2029 illustrate how the market is set to change.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

  • Get a detailed picture of the Rx/Reimbursement adult incontinence market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.

Table of Contents

KEY DATA FINDINGS
2024 DEVELOPMENTS
  • The ageing population supports ongoing retail value growth in 2024
  • Essity leads the competitive landscape, offering its established Tena brand
  • Distribution is via online orders or in-person collection at pharmacies
PROSPECTS AND OPPORTUNITIES
  • Retail adult incontinence is set to record a value uplift as acceptance widens
  • Innovation is expected to focus on sustainability, aligning with societal concerns
  • Assessments may become more stringent across the forecast period
CATEGORY DATA
  • Table 1 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2019-2024
  • Table 2 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2019-2024
  • Table 3 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2024-2029
  • Table 4 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2024-2029
TISSUE AND HYGIENE IN DENMARK
EXECUTIVE SUMMARY
  • Tissue and hygiene in 2024: The big picture
  • 2024 key trends
  • Competitive landscape
  • Retail developments
  • What next for tissue and hygiene?
MARKET INDICATORS
  • Table 5 Birth Rates 2019-2024
  • Table 6 Infant Population 2019-2024
  • Table 7 Female Population by Age 2019-2024
  • Table 8 Total Population by Age 2019-2024
  • Table 9 Households 2019-2024
  • Table 10 Forecast Infant Population 2024-2029
  • Table 11 Forecast Female Population by Age 2024-2029
  • Table 12 Forecast Total Population by Age 2024-2029
  • Table 13 Forecast Households 2024-2029
MARKET DATA
  • Table 14 Retail Sales of Tissue and Hygiene by Category: Value 2019-2024
  • Table 15 Retail Sales of Tissue and Hygiene by Category: % Value Growth 2019-2024
  • Table 16 NBO Company Shares of Retail Tissue and Hygiene: % Value 2020-2024
  • Table 17 LBN Brand Shares of Retail Tissue and Hygiene: % Value 2021-2024
  • Table 18 Penetration of Private Label in Retail Tissue and Hygiene by Category: % Value 2019-2024
  • Table 19 Distribution of Retail Tissue and Hygiene by Format: % Value 2019-2024
  • Table 20 Distribution of Retail Tissue and Hygiene by Format and Category: % Value 2024
  • Table 21 Forecast Retail Sales of Tissue and Hygiene by Category: Value 2024-2029
  • Table 22 Forecast Retail Sales of Tissue and Hygiene by Category: % Value Growth 2024-2029
DISCLAIMER
SOURCES
  • Summary 1 Research Sources